BeyondSpring Inc. (BYSI) EPS Estimated At $-0.73

May 7, 2018 - By Vivian Currie

Analysts expect BeyondSpring Inc. (NASDAQ:BYSI) to report $-0.73 EPS on May, 28.They anticipate $1.93 EPS change or 72.56 % from last quarter’s $-2.66 EPS. After having $-0.68 EPS previously, BeyondSpring Inc.’s analysts see 7.35 % EPS growth. The stock increased 0.72% or $0.21 during the last trading session, reaching $29.51. About 12,581 shares traded. BeyondSpring Inc. (NASDAQ:BYSI) has 0.00% since May 7, 2017 and is . It has underperformed by 11.55% the S&P500.

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company has market cap of $662.67 million. The firm is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. It currently has negative earnings.

More news for BeyondSpring Inc. (NASDAQ:BYSI) were recently published by: Globenewswire.com, which released: “BeyondSpring to Present Neutropenia Clinical Trial Data on Lead Asset, Plinabulin, at 2018 ASCO Annual Meeting” on April 25, 2018. Nasdaq.com‘s article titled: “BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia” and published on April 17, 2018 is yet another important article.

BeyondSpring Inc. (NASDAQ:BYSI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.